Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tubulin-folding cofactor A (TBCA) is a cytosolic protein chaperone that captures and stabilizes β-tubulin intermediates during folding, directly influencing the formation of functional α/β-tubulin heterodimers necessary for microtubule construction. TBCA is an essential component for microtubule dynamics, cell structure maintenance, and cell cycle progression. Experimental downregulation of TBCA leads to microtubule disorganization, reduced tubulin pools, cell cycle arrest, and cell death. TBCA dysregulation has been implicated in cancer metastasis and may have roles in metabolic diseases such as obesity.
For future TBCA-targeting therapeutics, mechanisms would likely include inhibition of β-tubulin folding, disruption of microtubule assembly, induction of cell cycle arrest, and modulation of cytoskeletal structure. No currently approved drugs directly target TBCA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin-folding cofactor A (TBCA).